2023 World Conference on Lung Cancer (Posters)-P2.17. Efficacy of Platinum after Lurbinectedin + DOX or Topotecan/CAV in Sensitive Relapsed SCLC Patients in the ATLANTIS Trial

P2.17. Efficacy of Platinum after Lurbinectedin + DOX or Topotecan/CAV in Sensitive Relapsed SCLC Patients in the ATLANTIS Trial - PDF(Slides)

Back to course

Pdf Summary

The ATLANTIS trial examined the efficacy of platinum rechallenge in patients with platinum-sensitive relapsed small cell lung cancer (SCLC) after treatment with lurbinectedin, doxorubicin (DOX), or topotecan/CAV. The study found that immediate platinum rechallenge after lurbinectedin and DOX resulted in longer survival compared to rechallenge after topotecan/CAV. This could be due to lurbinectedin leading to a longer median progression-free survival (PFS) compared to topotecan/CAV. The effects of platinum rechallenge after lurbinectedin were similar to those reported after second-line treatment, suggesting that lurbinectedin as a second-line treatment does not impact the efficacy of subsequent platinum rechallenge. Additionally, lurbinectedin may extend the platinum-free interval and improve patient survival.<br /><br />The study analyzed patients enrolled in the ATLANTIS trial who had a chemotherapy-free interval of 90 days. Of these patients, a total of 205 received topotecan/CAV and 208 received lurbinectedin and DOX. Immediate platinum rechallenge was given to 28 patients in the lurbinectedin and DOX group and 30 patients in the topotecan/CAV group. The lurbinectedin and DOX group showed higher overall response rates (ORR) and longer median duration of response, PFS, and overall survival (OS) compared to the topotecan/CAV group. The median PFS during platinum rechallenge was similar in both groups, but the median OS was longer in the lurbinectedin and DOX group.<br /><br />There were no significant differences in baseline characteristics between the two groups, including ECOG performance status, central nervous system involvement, time from diagnosis to randomization, or response to prior platinum treatment.<br /><br />In conclusion, platinum rechallenge immediately after lurbinectedin and DOX showed improved survival outcomes compared to rechallenge after topotecan/CAV in patients with platinum-sensitive relapsed SCLC. This suggests that lurbinectedin as a second-line treatment does not compromise the efficacy of subsequent platinum rechallenge and may extend the platinum-free interval, leading to improved patient outcomes.

Asset Subtitle

Jose Antonio Lopez-Vilariño

Meta Tag

Speaker Jose Antonio Lopez-Vilariño

Topic SCLC & Neuroendocrine Tumors: Relapse & Salvage Therapy

Keywords

ATLANTIS trial

platinum rechallenge

platinum-sensitive relapsed small cell lung cancer

SCLC

lurbinectedin

doxorubicin

topotecan/CAV

progression-free survival

chemotherapy-free interval

overall survival